SCHEMBL4723779

SCHEMBL4723779

CCCOc1ccn[c]c1-c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 1/20 0.40
HTR7 P34969 1/20 0.36
NLRP3 Q96P20 1/20 0.35
ADRB2 P07550 1/20 0.35
PDE5A O76074 2/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
GCGR P47871 1/20 0.34
MAPK14 Q16539 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
TSHR P16473 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MCHR1 Q99705 1/20 0.34
ALDH1A1 P00352 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4719732 0.92 CYP2C9 (0.42) TLR8MAPTALDH1A1NPC1RAB9A
SCHEMBL4765578 0.87 ALDH1A1 (0.38) TLR8MAPTNPSR1ALDH1A1NPC1
SCHEMBL3766619 0.78 CA12 (0.38) LMNAMAPTTSHRALDH1A1NPC1
SCHEMBL4724637 0.77 HTR1B (0.43) TLR8PDE5APDE4APDE4BPDE4C
SCHEMBL4721580 0.77 MAPT (0.36) TLR8NLRP3ADRB2PDE5ALMNA
SCHEMBL2068642 0.75 TLR8 (0.38) TLR8PDE5APDE4APDE4BPDE4C
SCHEMBL3516825 0.73 TLR8 (0.37) TLR8PDE5APDE4APDE4BPDE4C
SCHEMBL4723556 0.72 ADORA3 (0.39) TLR8HTR7NLRP3ADRB2LMNA
SCHEMBL2068081 0.72 TLR8 (0.36) TLR8PDE4AMAPTMCHR1ALDH1A1
SCHEMBL2066562 0.72 TLR8 (0.36) TLR8PDE5APDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 TLR8 1678/4885HTR7 136/4885NLRP3 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.